Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
EC grants conditional marketing authorization based on the EFFISAYIL trial
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Subscribe To Our Newsletter & Stay Updated
